If you have been diagnosed with ulcerative colitis (UC), there is a strong chance your gastroenterologist has prescribed a 5-ASA medication. These drugs form the backbone of treatment for mild to moderate disease, and many people with UC take them for years to control inflammation and maintain remission.
What are 5-ASAs?
5-ASA stands for 5-aminosalicylic acid, also known as mesalazine or mesalamine. It is an anti-inflammatory drug that works locally in the gut lining to reduce inflammation. Unlike systemic immunosuppressants, 5-ASAs act primarily at the surface of the intestinal wall, where ulcerative colitis inflammation occurs. They are chemically related to aspirin but formulated to release their active ingredient in the colon rather than being absorbed higher up in the digestive tract.
Several different 5-ASA formulations are available. Some use pH-dependent coatings that dissolve at a specific acidity level, releasing the drug in the terminal ileum or colon. Others use time-dependent release or are packaged as prodrugs, such as sulfasalazine or balsalazide, which are broken down by bacteria in the colon to release 5-ASA. Rectal formulations, including suppositories and enemas, deliver the drug directly to the rectum and left side of the colon, where inflammation is often most active.
Why 5-ASAs matter in ulcerative colitis
Ulcerative colitis involves chronic inflammation of the colon and rectum lining. Left unchecked, this inflammation damages the mucosal barrier, increases the risk of flares, and over time can raise the risk of complications including colorectal cancer. 5-ASAs help control that inflammation, reduce symptoms such as bleeding and diarrhoea, and support long-term remission.
Crucially, 5-ASAs have a well-established safety profile. They can be used for extended periods with relatively few side effects compared to corticosteroids or biologic therapies. This makes them particularly suitable for maintenance treatment, where the goal is to keep inflammation suppressed and prevent future episodes.
How 5-ASAs reduce gut inflammation
Local anti-inflammatory action
5-ASAs work by inhibiting several pathways that drive inflammation in the gut lining. They interfere with the production of prostaglandins and leukotrienes, signalling molecules that promote inflammation and recruit immune cells. By dampening these signals, 5-ASAs reduce the intensity of the inflammatory response in the colonic mucosa.
Nuclear factor kappa B inhibition
One key mechanism involves blocking nuclear factor kappa B (NF-κB), a protein complex that controls the expression of genes involved in inflammation. When NF-κB is activated, it triggers the release of pro-inflammatory cytokines such as tumour necrosis factor alpha (TNF-α) and interleukin-1. 5-ASAs suppress NF-κB activity, reducing cytokine production and helping to quiet the immune response in the gut.
Antioxidant effects
Inflammation generates reactive oxygen species, unstable molecules that can damage cells and perpetuate tissue injury. 5-ASAs have antioxidant properties that help neutralise these reactive molecules, protecting the gut lining and supporting mucosal healing. This effect complements their direct anti-inflammatory action.
Modulation of the mucosal barrier
A healthy intestinal lining acts as a selective barrier, allowing nutrients to pass whilst keeping bacteria and toxins out. In ulcerative colitis, this barrier is compromised. 5-ASAs appear to support epithelial repair and improve mucosal barrier integrity, reducing permeability and limiting immune cell exposure to bacterial antigens that can trigger further inflammation.
Formulations and delivery
The effectiveness of 5-ASAs depends on delivering the active drug to the site of inflammation. Oral tablets and capsules are designed to resist breakdown in the stomach and small intestine, releasing their contents in the colon. Your gastroenterologist will choose a formulation based on the extent and location of your disease.
For people with left-sided colitis or proctitis, rectal preparations such as suppositories, foams, or enemas can be highly effective. These deliver a concentrated dose directly to the inflamed tissue and are often used alongside oral therapy during a flare, or alone for maintenance if inflammation is confined to the rectum and sigmoid colon.
Efficacy and expectations
5-ASAs are most effective for mild to moderate ulcerative colitis. They induce remission in a proportion of people with active disease and are widely used to maintain remission once inflammation has settled. Response rates vary, and some people require additional treatment with corticosteroids, immunomodulators, or biologics if 5-ASAs alone are insufficient.
5-ASAs work gradually. Symptom improvement may take several weeks, and mucosal healing can take longer still. Adherence is critical. Taking 5-ASAs consistently, even when you feel well, reduces the risk of relapse and supports long-term disease control. Stopping treatment during remission significantly increases the chance of a flare.
Side effects and monitoring
Most people tolerate 5-ASAs well. Common side effects include headache, nausea, abdominal discomfort, and diarrhoea. These are usually mild. Rarely, 5-ASAs can cause a paradoxical worsening of colitis symptoms or hypersensitivity reactions such as rash, fever, or chest pain. If you experience new or worsening symptoms after starting a 5-ASA, contact your healthcare team promptly.
Kidney function should be monitored periodically, as 5-ASAs can occasionally affect the kidneys. Blood tests are typically checked before starting treatment and then annually, or more often if you have pre-existing kidney concerns.
Practical takeaways
- Take 5-ASAs exactly as prescribed, even during remission, to reduce the risk of flares.
- If you are using rectal preparations, try to retain them for as long as possible to maximise contact with the inflamed tissue.
- Attend regular follow-up appointments and monitoring blood tests as recommended by your gastroenterology team.
- Do not stop or reduce your medication without consulting your doctor, even if your symptoms improve.
- Report any new or unusual symptoms, particularly fever, rash, chest pain, or worsening diarrhoea, to your healthcare provider.
- Remember that 5-ASAs control inflammation but do not cure ulcerative colitis. Ongoing treatment and monitoring are part of long-term disease management.
Conclusion
5-ASAs remain the foundation of treatment for many people with ulcerative colitis. They work by targeting inflammation directly in the gut lining, supporting mucosal healing, and reducing the frequency of flares. Whilst they are not effective for everyone, their safety profile and proven track record make them an essential tool for long-term disease control. Consistent use, regular monitoring, and open communication with your gastroenterology team will help you get the most from this treatment.
References
- Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000543. doi:10.1002/14651858.CD000543.pub2
- Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10:CD000544. doi:10.1002/14651858.CD000544.pub3
- Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991-1030. doi:10.1016/j.crohns.2012.09.002
- Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17(1):29-42. doi:10.1046/j.1365-2036.2003.01408.x
- Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2010;(1):CD004115. doi:10.1002/14651858.CD004115.pub2
- Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005;201(8):1205-1215. doi:10.1084/jem.20041948
- Kruis W, Schreiber S, Theuer D, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut. 2001;49(6):783-789. doi:10.1136/gut.49.6.783
- Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114(1):39-43. doi:10.1016/s0002-9343(02)01383-9
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.